Wednesday, 28 Jun 2017

You are here

Educational Intervention Facilitates Treat-to-Target Management in Rheumatoid Arthritis

Treat-to-target (TTT) has become a goal in rheumatoid arthritis (RA) therapeutics, but its implementation in daily practice is varied and viewed to be difficult by most. Solomon and coworkers have shown that TTT education through group-based quality improvement sessions can result in wider use of TTT in practice.

They set out to study the adherence to TTT in practice using a randomized quality improvement intervention with wait-list control across 11 rheumatology sites in the US.

The intervention utilized was a "learning collaborative" effort to establish best practices. These group-based learning collaboratives used rapid cycle testing for change along with frequent assessment of quality care improvements.

For 9-months the LC group incorporated rapid-cycle improvement methods. A composite TTT implementation score was a percentage of four required items documented in the chart. These included: 1) a disease activity target; 2) recording RA disease activity,numerically or by category (i.e., remission, low disease activity, etc.) using either the DAS28, SDAI, CDAI, or RAPID3; 3) documenting shared-decision making; and 4) documenting treatment decisions based on target and disease activity measure.

Five sites (23 providers) were randomized to intervention  and managed 320 patients, while six sites (23 provider) were randomized to the wait-list control, managing 321 patients.

At study start a minority utilized TTT with mean TTT implementation score of 11%.  After  9 months, the TTT implementation score was higher with the LC intervention (57% vs 25% in control).

Substantial improvement in TTT utilization was seen with this learning collaborative intervention.  

While nearly half of all rheumatologists utilize some disease measure in practice, there is little evidence that they utilize this information in daily patient management.  These findings suggest that knowing and using the measure in the clinic may not be enough and that a substantial committment to quality care and specific educational interventions are needed to demonstrate treatment decisions based on disease activity measures in RA.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Approves Abatacept for Pediatric Use

Subcutaneous (SC) abatacept (Orencia) is now available for use in patients 2 years of age and older with moderately to severely active polyarticular Juvenile Idiopathic (JIA) according to Bristol-Myers Squibb.  Orencia was previously approved for use in adults with rheumatoid arthritis (RA) and was FDA approved for pediatric use in March 2017.

Nurse-Led Patient Care in Rheumatology

Manpower in rheumatology is about to be a major problem for the next several decades: not enough trainees, a "tsunami of retiring older white rheumatologists", and an aging baby-boomer, arthritis-primed population will strain current resources and manpower.  Moreover, necessary services will not likely be available to those in need and there may be a significant maldistribution of adequate rheumatologic care.

Both Undertreatment and Overtreatment Common in JIA

Kimme L. Hyrich, MD, PhD, of the University of Manchester in the United Kingdom, and colleagues point out that because of the lack of consensus in diagnostic criteria, "the same child could be classified as 'in clinically inactive disease' or having active disease at the same time point between clinicians or hospitals."

Biologics Before Triple DMARD is Not Cost Effective in Rheumatoid Arthritis

Stepping up to biologic therapy when methotrexate (MTX) monotherapy fails was not shown to be cost effective, compared to first trying triple therapy, in a rheumatoid arthritis (RA) study published in Annals of Internal Medicine.

NLRP3 Activation in Still's Disease

Adult-onset Still disease (AOSD) is usually regarded as an autoinflammatory disease, largely because of its symptomatology and responsiveness to IL-1 inhibition.  Thus while it is assumed that aberrant NLRP3 inflammasome activity underlies active AOSD, the connection between NLRP3 AOSD has yet to be solidfied.